Interim Report January - September 2007

KEY EVENTS DURING THE PERIOD
- Net revenues amounted to MSEK 21.7 (80.3)
- The loss after tax was MSEK 128.6 (loss: 20.5)
- Earnings per share amounted to a loss of SEK 9.24 (loss: 1.54)
- Orexo establishes a sales force in the Nordic markets by forming a joint venture with ProStrakan
- The EU registration process of Rapinyl® has been referred to EMEA’s Committee for Medicinal Products for Human Use (CHMP)

THIRD QUARTER 2007
- Net revenues amounted to MSEK 6.5 (24.9)
- The loss after tax was MSEK 34.1 (loss: 11.2)
- Earnings per share amounted to a loss per share was SEK 2.44 (loss: 0.84)

KEY EVENTS AFTER THE PERIOD
- Orexo enters agreement to acquire Biolipox – first step in creating innovative specialty pharma company
- Orexo to convene Extraordinary General Meeting on November 1, 2007
- Orexo reports positive results in comparative clinical Phase III trials for Sublinox™ (OX22)
- Orexo commences phase 1 trials for its incontinence treatment
- Orexo broadens its portfolio in pain relief – commences two new development projects